The inhibition of apoptotic changes in vascular endothelial cells is important for preventing vascular damage from hypoxia. AMP-activated protein kinase (AMPK) has recently been identified as playing a role in vascular protection. Although the chemical reagent 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) has been used to stimulate AMPK activity, AICAR has been associated with several nonspecific reactions. We therefore constructed a new constitutively active mutant of AMPKa1 (NcaAMPK), which lacks the autoinhibitory domain in AMPKa1 and in which threonine 172 has been replaced with aspartate. We investigated whether NcaAMPK has an anti-apoptotic effect in vascular endothelial cells under anoxic conditions. NcaAMPK, or green fluorescent protein (GFP) as a control, was overexpressed in human umbilical vein endothelial cells (HUVECs). After HUVECs were incubated for 40 h under normoxic or anoxic conditions, we examined cell viability, caspase 3/7 activity, and expression and phosphorylation levels of apoptosis-related proteins. Cell viabilities under anoxic conditions were improved in NcaAMPK-overexpressing cells. Anoxia increased caspase 3/7 activity, but NcaAMPK reduced this increase significantly. NcaAMPK overexpression increased protein kinase B/Akt Ser473 and endothelial nitric oxide synthase Ser1177 phosphorylation, but pretreatment with the nitric oxide synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME) did not decrease the viability of NcaAMPK-overexpressing HUVECs. Furthermore, co-expression of a dominant-negative Akt reduced the improvement in cell viability and the suppression of poly (ADP-ribose) polymerase cleavage by NcaAMPK under anoxic conditions. In conclusion, NcaAMPK inhibited anoxia-induced apoptosis in vascular endothelial cells through Akt activation, suggesting that activation of AMPK might protect against ischemic vascular injury.
INTRODUCTION
An important initial step in the pathogenesis of atherosclerosis is endothelial damage by various factors, such as inflammatory cytokines. 1 A large body of evidence has shown that hypoxia is a pivotal factor modulating endothelial cell function and survival. 2 Although necrosis is a major pathway for regulating ischemia-and reperfusioninduced cardiomyocyte death, apoptosis has recently been identified as another important regulator. 3 Furthermore, apoptosis of vascular endothelial cells is thought to be a pivotal regulator of vascular damage, suggesting that apoptosis of endothelial cells could be an important therapeutic target for preventing cardiovascular diseases.
AMP-activated protein kinase (AMPK) has been identified as a key regulator of cellular ATP levels. 4 AMPK was identified as a homolog of yeast sucrose non-fermenting 1 and is known as a metabolite-sensing protein kinase. 5 AMPK is a heterotrimeric serine/threonine protein kinase consisting of a catalytic a-subunit and two regulatory subunits, b and g. 6 There are multiple isoforms of each AMPK subunit, with a1, a2, b1, b2, g1, g2, and g3 forming heterotrimers 7 that differ in tissue and subcellular localization. In mammalian cells, AMPK is activated by increases in the AMP/ATP ratio, 4 which occur under conditions of hypoxia or anoxia. 8, 9 When the AMP/ATP ratio increases, AMPK is partially activated by a conformational change after combining with AMP and is fully activated when phosphorylated at Thr172 by an AMPK kinase (AMPKK), which is now known to be LKB1 serine/ threonine kinase. 10 Activated AMPK phosphorylates and downregulates several anabolic enzymes, including 3-hydroxy-3-methylglutarylCoA reductase or acetyl-CoA carboxylase, and shuts off the ATPconsuming synthetic pathway. 4 In addition to such energy-saving effects, AMPK is important for protecting cellular function under energy-restricted conditions, such as hypoxia/anoxia. 11 To investigate the functions of AMPK in mammalian cells, we and other investigators have used 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR), which is a chemical AMPK activator. AICAR is phosphorylated and converted to 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranosyl-5¢-monophosphate (ZMP) in mammalian cells. ZMP mimics the effect of AMP and activates AMPK. 12, 13 However, AICAR increases not only ZMP but also ZTP 12 and, as a chemical rather than a specific enzyme, may have other nonspecific effects on ATP-requiring reactions. Constitutively active mutants of AMPK provide a more specific method for examining the functions of AMPK. Several kinds of constitutively active AMPK mutants have been investigated, including AMPKa1 (amino acids (aa) 1-312, Thr172-Asp: T172D), 14, 15 AMPKg2 (Arg302-Gln), 16 and AMPKg1 (His150-Arg). 17 Although it has been reported that maximum activity of AMPK requires all three subunits, 6 AMPKa1 (1-312, T172D) lacks both the binding domain for interactions with the b-subunit and the autoinhibitory domain, which inhibits the self-kinase activity. 14 The b-subunit plays a role in modulating subcellular localization through its phosphorylation and myristoylation, 18, 19 so that the ability to bind the b-subunit might be critical for the catalytic a-subunit to select its appropriate substrates. We have constructed a replication-defective adenoviral vector expressing a new constitutively active AMPKa1 mutant (NcaAMPK), which lacks the autoinhibitory domain (aa 313-392) but has the complex formation domain (aa 393-548). 14 As we found that NcaAMPK functions as a specific and continuous activator of AMPK, we investigated whether NcaAMPK overexpression could inhibit the pro-apoptotic pathway induced by anoxia in human umbilical vein endothelial cells (HUVECs).
MATERIALS AND METHODS

Chemical reagents
N G -nitro-L-arginine methyl ester (L-NAME), wortmannin, and other chemical reagents were purchased from Sigma-Aldrich (St Louis, MO, USA).
Antibodies
AMPKa1, phospho-AMPKa (Thr172), phospho-protein kinase B/Akt (Ser473), phospho-endothelial nitric oxide synthase (eNOS) (Ser1177), and poly (ADP-ribose) polymerase (PARP) antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Actin, Akt, and eNOS antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Myc-tag and hemagglutinin (HA)-tag antibodies were purchased from Upstate Biotechnology (Lake Placid, NY, USA).
Cell culture and anoxic conditions
HUVECs were purchased from Kurabo (Osaka, Japan) and cultured in HuMedia EG2 (Kurabo). HUVECs were used for experiments within passages 6-8. In some experiments, HUVECs were transduced with the indicated replication-defective adenoviral vectors at a multiplicity of infection of 50 plaque-forming units (50 MOI) for 1 day. The medium was then changed to a low-serum medium, HuMedia basic medium (EB2) with 0.2% fetal bovine serum, to reduce the effects of stimulation by serum mitogens.
After incubation in the low-serum medium for 8 h, adenovirus-infected cells were incubated in a normoxic or anoxic incubator for 40 h. In the pilot experiments, we found that 24 h anoxia was too short to evaluate cell viability because cell survival rates under these conditions were 490%. Furthermore, even under normoxic conditions, 472 h incubation in the low-serum medium induced high rates of cell death 440%. We conclude that 40-48 h anoxic conditions are suitable for evaluating effects of anoxia on cell death without the cell-damaging effects of low serum. For anoxic conditions, we used the Anoxic Chamber System (Coy Laboratory Products, Grass Lake, MI, USA). To exclude the effects of reoxygenation after anoxia, every procedure (such as protein extraction) was performed under anoxic conditions in this anoxic chamber.
Construction of adenoviral AMPKa1 mutant vectors and other adenoviral vectors
Total RNA was extracted from rat vascular smooth muscle cells (rVSMCs) using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was produced by reverse transcription from purified rVSMC RNA with an RNA LA PCR kit (TAKARA, Otsu, Japan) using a random 9mer primer. Synthetic oligo primers for PCR and for creating point mutations are as follows:
To make a conventional caAMPK (CcaAMPK) cDNA fragment that lacks aa 313-548, we performed PCR with KOD FX DNA polymerase (Toyobo, Osaka, Japan) using the rVSMC cDNA, primer 1 (which includes a myc-tag sequence), and primer 2. This fragment was digested with the restriction enzymes EcoRI and XhoI and ligated to pcDNA 3.1/Zeo(+) (Invitrogen) digested with EcoRI/ XhoI. To make a Thr-to-Asp mutation at residue 172, we used a QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions, using primers 6 and 7 to introduce the point mutation. To construct the NcaAMPK cDNA fragment, which has the complex formation domain but lacks the autoinhibitory domain, we amplified a fragment A using primer 1/primer 3 and a fragment B using primer 4/primer 5. We digested fragments A and B with EcoRI/XbaI and XbaI, respectively. Fragment A was then ligated to pcDNA 3.1/Zeo(+) digested with EcoRI/XbaI. Next, this vector was digested with XbaI and ligated with XbaI-digested fragment B. The direction of fragment B was confirmed by direct sequencing. To make a Thr-to-Asp mutation at residue 172, we used the QuickChange II XL Site-Directed Mutagenesis Kit, as for CcaAMPK construction. Schematics of the complete constructs are shown in Figure 1 . We used an adenoviral construction kit (AdEasy adenovirus vector system; Stratagene) to make replication-defective adenoviral vectors for CcaAMPK and NcaAMPK. Briefly, pcDNA 3.1/Zeo(+) plasmid vectors for CcaAMPK and NcaAMPK were digested with KpnI/XhoI, and the fragments were ligated to a KpnI/XhoIdigested pAdTrack-CMV plasmid, which was a generous gift from Dr Walsh (Boston University). We followed the manufacturer's instructions after this procedure. An adenoviral vector expressing green fluorescent protein (GFP) was obtained from Qbiogene (Illkirch, France) and used as a control for infection level. The HA-tagged dominant-negative (dn) Akt adenovirus was also generous gift from Dr Walsh.
AMPK assay
The AMPK assay using SAMS peptide (HMRSAMSGLHLVKRR, Upstate Biotechnology) was performed according to the methods available at the Animal Model of Diabetic Complications Consortium (AMDCC) website (http://www.amdcc.org/shared/phenotype/showAssay.aspx?id¼260).
Western blot analysis
Western blot analysis was carried out as previously described. 9 An ECL-PLUS Western Blotting Detection kit (GE Healthcare, Piscataway, NJ, USA) was used AMPK inhibits anoxia-induced apoptosis of HUVECs D Nagata et al for detection. The density of the bands was quantified using the Scion Image program (Scion Corporation, Frederick, MD, USA). Each experiment was repeated 3-4 times.
Intracellular protein crosslinking experiments using photoactivated amino acids
To evaluate intracellular AMPK protein complex formation in NcaAMPKoverexpressing cells, we used the photoactivated amino acid system (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer's instructions. Briefly, ultraviolet (UV)-sensitive L-photo-leucine and L-photo-methionine, which are incorporated in AMPK subunits or overexpressed AMPK mutants, are crosslinked to each other intracellularly after UV irradiation. Cell lysates were then extracted with cell lysis buffer, and AMPK protein complex formation was evaluated by western blotting.
WST-1 assay
To evaluate cell viability, we performed an assay using the WST-1 reagent (Roche, Basel, Switzerland) according to the manufacturer's instructions.
Caspase 3/7 assay
We performed a caspase 3/7 assay using a Caspase-Glo 3/7 assay kit and GloMax96 luminometer (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Statistical analyses
Values are expressed as the mean±s.e.m. Statistical comparisons were performed using analysis of variance with Scheffe's F procedure for post hoc analyses. P-valueo0.05 was considered to be statistically significant.
RESULTS
NcaAMPK shows higher kinase activity and forms an AMPK complex more efficiently than CcaAMPK
To compare the AMPK activity of NcaAMPK and CcaAMPK, we performed a kinase assay by measuring the radiolabeled phosphorylation rate of SAMS peptide corrected by the amount of protein (Figure 2a We confirmed the expression of the CcaAMPK and NcaAMPK mutants by western blot ( Figure 2b ). As NcaAMPK kinase activity is higher than CcaAMPK, we hypothesized that NcaAMPK would bind more effectively to the b-subunit than CcaAMPK and its kinase activity would be intensified. To show the formation of AMPK complexes including NcaAMPK, we used the UV light-sensitive photoactivated amino acid system. In NcaAMPKoverexpressing HUVECs, positive bands of approximately 130 kDa were found when using an anti-myc-tag or anti-AMPKb antibody (Figure 2c ). In CcaAMPK-overexpressing cells, we did not find myctag positive bands of approximately 110 kDa, which indicates AMPK complex formation including the CcaAMPK mutant. When using the AMPKb antibody, we found weaker intensity bands with a molecular weight of B135 kDa in the GFP-and CcaAMPK-overexpressing cells. These might be endogenous AMPK complexes with expected molecular weights of 137 kDa (a1b1g1 or a2b1g1). These results suggest that NcaAMPK, which has the complex formation domain, can form active AMPK complexes more effectively than CcaAMPK.
NcaAMPK overexpression inhibits anoxia-induced cell death
We performed a WST-1 assay in HUVECs overexpressing GFP, CcaAMPK, or NcaAMPK to compare the effect of the AMPK mutants on cell survival under anoxic conditions. Cell viability was significantly higher (Po0.01) in NcaAMPK-overexpressing cells than in either GFP or CcaAMPK-infected cells (Figure 3a) . The lower panels in Figure 3a show phase-contrast micrographs of these cells. NcaAMPK overexpression inhibited cell death and kept cells attached to the bottom of the culture dish.
We also measured caspase 3/7 activity to investigate whether anoxia-induced cell death might be accompanied by an increase in caspase activity. Caspase 3/7 activity was inhibited by 33% in NcaAMPK cells relative to control GFP cells (Figure 3b ). CcaAMPK did not inhibit caspase 3/7 compared with controls ( Figure 3b ).
NcaAMPK increases Akt and eNOS phosphorylation
Previous studies, including ours, suggested that AMPK upregulates the PKB/Akt signal, 9, 20 which is known to be an important regulator of cell survival in endothelial cells. Consistent with these reports, we found that Akt Ser473 was more highly phosphorylated in NcaAMPKoverexpressing cells than in controls (Figure 4a) . Furthermore, eNOS Figure 1 The construction of two AMPKa1 mutants, conventional constitutively active a1 (CcaAMPK) and new constitutively active a1 (NcaAMPK). Wildtype rat AMPKa1 contains a kinase domain, autoinhibitory domain, and the domain for complex formation. The autoinhibitory domain inhibits the AMPKa1 kinase activity. CcaAMPK lacks both the autoinhibitory domain and the domain for complex formation. At the target phosphorylation site of upstream kinases in the kinase domain of CcaAMPK, Asp was substituted for Thr172 to mimic phosphorylation. We constructed NcaAMPK by adding the domain for complex formation to the C terminus of CcaAMPK. Both CcaAMPK and NcaAMPK have a myc tag to distinguish their expression from that of endogenous AMPKa1.
AMPK inhibits anoxia-induced apoptosis of HUVECs D Nagata et al
Ser1177, which is known to be phosphorylated by Akt and AMPK, 21 was also phosphorylated (Figure 4a ). Phosphoinositide 3 (PI3) kinase is an upstream kinase of Akt, and pretreatment with the PI3 kinase inhibitor wortmannin (1 mmol l À1 ) inhibited Akt and eNOS phosphorylation (Figures 4a and b) , suggesting that NcaAMPK phosphorylates Akt and eNOS in a PI3 kinase-dependent manner. Thus, eNOS might be phosphorylated both directly by AMPK and, at least in part, by the PI3-Akt pathway.
As we have previously shown that nitric oxide has an anti-apoptotic effect in endothelial cells, 22 we used the WST-1 assay to investigate whether the nitric oxide synthase inhibitor L-NAME could inhibit the anti-apoptotic cell survival effect of NcaAMPK. Although we used L-NAME concentrations from 1.0 to 5.0 mmol l À1 , L-NAME pretreatment did not inhibit cell survival (Figure 4c ).
NcaAMPK increases the phosphorylation of Akt but does not modulate proteins of the bcl-2 family
In agreement with the results of our previous report, 9 the phosphorylation of Akt Ser473 decreased under anoxic conditions in control cells (Figures 5a and b) . However, in NcaAMPK-overexpressing cells, Akt phosphorylation was maintained at a high level even under anoxic conditions. The expression levels of two members of the Bcl-2 family, Bax and Bcl-xl, did not change in NcaAMPK-overexpressing cells or under anoxic conditions (Figure 5a ). Bcl-2 was not detected by western blot analysis.
NcaAMPK suppresses anoxia-induced cell death and PARP cleavage but co-expression of dnAkt abrogates this suppression We showed that NcaAMPK overexpression augments the resistance of HUVECs to anoxia (Figure 3) . However, co-expression of dnAkt partially but significantly abrogated this anoxia resistance in NcaAMPK-overexpressing cells (Figure 6a ). Next, we performed western blot analyses to investigate whether PARP cleavage was inhibited more effectively in NcaAMPK-overexpressing cells than in controls. The band intensities of cleaved PARP were higher under anoxic conditions than under normoxic conditions. The band intensity of the cleaved smaller fragment of PARP was lower in NcaAMPKoverexpressing cells than in controls under anoxic conditions (Figure 6b, lane 4) . However, overexpression of dnAkt partially but 
DISCUSSION
The results of this study suggest that AMPK activation by NcaAMPK inhibits anoxia-induced apoptosis in HUVECs through the activation of Akt. Although ischemia and reperfusion have been shown to injure the cardiovascular system, AMPK activation can prevent these harmful effects of ischemia. 23 AMPK is also a downstream target of adiponectin, 24 ,25 the most cardiovascular-protective adipocytokine, 26 which inhibits cardiomyocyte apoptosis partially through AMPK activation. 27 Conversely, apoptosis increases in cardiomyocytes after ischemia and reperfusion when AMPK activation is impaired. 23 Thus, AMPK clearly plays an anti-apoptotic role in the cardiovascular system, although details of the mechanism remain to be elucidated, especially in the vasculature. Some investigators 28, 29 have shown that AICAR-induced AMPK activation inhibits apoptosis in vascular endothelial cells, whereas other investigators 30, 31 have reported that AICAR treatment, rather than increasing cell viability, actually promotes apoptotic changes in nonendothelial cell lines. AICAR has also been reported to have nonspecific effects in addition to its ability to activate AMPK. 12, 32, 33 Therefore, we have been very eager to find a more specific activator of AMPK to clarify whether AMPK signaling actually inhibits anoxiainduced apoptosis in vascular endothelial cells. A constitutively active AMPK mutant containing only the a-subunit kinase domain, CcaAMPK, provided an alternative, but the kinase domain alone possesses weak kinase activity in mammalian cells, and maximum AMPK activity requires all three subunits. 6, 14 We therefore constructed a replication-defective adenovirus expressing NcaAMPK, which has higher kinase activity and suppresses anoxia-induced apoptotic cell death more efficiently than CcaAMPK. Although higher dose, 100 MOI, CcaAMPK transduction in the cells increased SAMS peptide phosphorylation rate by B35% compared with 50 MOI, the dose we used in this study, we did not find more potent inhibition of cell death in CcaAMPK-overexpressing cells with 100 MOI (data not shown). Our results suggest that the ability of NcaAMPK to bind the b-subunit might contribute to its more effective suppression of anoxia-induced apoptosis than that of CcaAMPK.
It has been previously reported that Akt is phosphorylated and activated in AMPK-activated endothelial cells, 9, 20, 34 and this activation is PI3-kinase dependent. 20, 34 In this study we found that Akt Ser473 was also phosphorylated in NcaAMPK-overexpressing HUVECs. PI3 kinase inhibition by wortmannin suppressed this Akt phosphorylation, suggesting that NcaAMPK also upregulates Akt in a PI3 kinasedependent manner. The anti-apoptotic effect of Akt has been proposed to be partially due tophosphorylation of transcription factors of the forkhead box gene, group O (FoxOs) and Bcl-xL/Bcl-2-associated death promoter (Bad). [35] [36] [37] As we reported previously that phosphorylation levels of Akt were gradually downregulated under hypoxic AMPK inhibits anoxia-induced apoptosis of HUVECs D Nagata et al conditions, 9 we also found in this study that the basal phosphorylation levels of Akt were lower under anoxic conditions than in normoxic conditions ( Figure 5 ). However, phosphorylation was maintained at high levels in NcaAMPK-overexpressing cells even under anoxic conditions. As overexpression of dnAkt did not reverse completely the inhibition of anoxia-induced PARP cleavage in NcaAMPK-overexpressing HUVECs, we suggest that NcaAMPK inhibits apoptosis of endothelial cells not only through Akt signaling but also through other, as yet unknown, signaling pathways under anoxic conditions. Very recently, Young 11 published a thought-provoking review on the function of AMPK in the cardiovascular system under ischemic stress. He suggested that AMPK functions as a 'major conductor of the stress signaling orchestra' in ischemic cardiovascular cells. As AMPK functions as an energy sensor and inhibits ATP-consuming reactions in endothelial cells, improvement of intracellular energy status might be a major factor for preventing cell death under anoxic/hypoxic conditions. However, we revealed in this study that AMPK activation plays an anti-apoptotic role in HUVECs, at least partly through the Akt pathway under anoxic conditions. AMPK might therefore play a beneficial role in the ischemic vasculature, although the details of the mechanism remain to be elucidated. 
